Tirzepatide 5MG

Tirzepatide is a novel man-made analogue of gastro-inhibitory polypeptide (GIP). Its structure is made up of 39 amino acids, and it activates both GIP and GLP-1 (glucagon-like peptide) receptors. GIP and GLP-1 are the hormones that mediate insulin release from pancreatic cells.

Trizepatide regulates blood sugar levels by promoting the release of inulin, inhibiting glucagon secretion and increasing gastric emptying time. Research shows that it lowers blood glucose levels more effectively than GLP-1 or GIP alone.

Tirzepatide was developed by the company Eli Lilly, and they sought a patent in 2016 for its use in the treatment of type 2 diabetes. The novel medicine gained the interest of worldwide researchers for its antidiabetic and antiobesity effects. On our website, tirzepatide for sale is available for educational and experimental purposes.

From Pubchem

Synonyms: Mounjaro, LY3298176
Molecular Weight: 4813 g/mol
Molecular Formula: C225H348N48O68
CAS number: 2023788-19-2
PubChem CID: 163285897

1. Tirzepatide And Diabetes

FDA has already approved Tirzepatide for the management of type 2 diabetes after several successful phase 3 clinical trials in the SURPASS. These studies provide significant evidence of the superior efficacy of Tirzepatide compared to a placebo and other drugs. The results of SURPASS 3 trials showed the greater efficacy of tirzepatide (TZP) compared to Insulin Degludec. It also demonstrated that patients treated with TZP who achieved HbA1c level of <5.7% over the period of 52 weeks showed better results in terms of TIT, TTIT and glycemic variability compared to those who didn’t attain the target [1].

Another study indicates that TZP when combined with insulin glargine showed improvement in glycemic control in patients who didn’t respond to insulin glargine [2].

SURPASS 6 trial found that TZP can more effectively improve HbA1c and health-related quality of life (HRQoL) in diabetic patients compared to insulin lispro [3].

2. Tirzepatide For Weight loss

SURPASS 1-5 trials that looked into the anti-diabetic effect have also shown significant weight loss effect with TZP in diabetes type 2 patients. A meta-analysis of these studies reveals that 43% of patients treated with TZP lost more than 15kg of body weight [4]

In a SURAMOUNT trial 1, researchers investigated the safety and efficacy of tirzepatide in obese individuals. They recruited 2539 people in the study who were randomly assigned to receive SC TZP (5mg, 10mg, 15mg) or placebo for 72 weeks. The percentage of participants who lost more than 5% weight was 85% for 5mg, 89% for 10mg and 91% for 15mg, indicating its superior efficacy compared to placebo [5].

SURAMOUNT trial 2 studied its weight loss effect in diabetes type 2 patients. The study found that 79-83% of people treated with TZP experienced more than 5% weight loss compared to the control group (32%) [6].

3. Tirzepatide and Cardioprotective effects

A handful of studies reveal that tirzepetide might provide cardioprotective effects. In a study, TZP showed cardioprotective effects by reducing the inflammatory response and alleviating LPS-induced cardiac dysfunction in mice. Furthermore, it decreased cardiomyocyte apoptosis and the risk of ventricular arrhythmia by inhibiting TLR4/NF-kB/NLRP3 pathway [7].

The post-hoc mediation analysis of SURPASS clinical program observed a reduction of systolic blood pressure in patients treated with TZP owing to its weight loss effect [8]. Another study found that patients who were administered TZP experienced more reductions in triglyceride and LDL-C than those with insulin glargine [9].

4. Current Status of Tirzepatide

Tirzepatide is now available in the market for the management of type 2 diabetes. Further clinical trials (SURAMOUNT) are ongoing to prove its safety and efficacy for weight loss. At Element Sarms the option to purchase tirzepatide is restricted to research purposes. Only buy tirzepatide if you are a licensed researcher.

1. BERGENSTAL, R.M., et al., 764-P: Time in Range and Time in Tight Range in Tirzepatide-Treated Patients Achieving Normoglycemia in the SURPASS-3 CGM Substudy. Diabetes, 2023. 72(Supplement_1).
2. Dahl, D., et al., Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. Jama, 2022. 327(6): p. 534-545.
3. BOYE, K., et al., 753-P: Tirzepatide Improves HRQoL Compared with Insulin Lispro in Poorly Controlled Basal Insulin–Treated Adults with Long-Standing T2D (SURPASS-6). Diabetes, 2023. 72(Supplement_1).
4. Malecki, M., et al., IDF2022-0369 Predictors of Achieving Weight Loss ≥15% With Tirzepatide in People With Type 2 Diabetes From SURPASS 1-4. Diabetes Research and Clinical Practice, 2023.
5. Jastreboff, A.M., et al., Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022. 387(3): p. 205-216.
6. Garvey, W.T., et al., Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. The Lancet, 2023.
7. Liu, Q., et al., Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4/NF-kB/NLRP3 pathway. International Immunopharmacology, 2023. 120: p. 110311..
8. Lingvay, I., et al., Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovascular Diabetology, 2023. 22(1): p. 66.
9. Kahn, S., et al., IDF2022-0918 Tirzepatide Reduces Serum Triglyceride Irrespective of Fibrate Use in People With T2D at High CV Risk (SURPASS-4). Diabetes Research and Clinical Practice, 2023.